Search PubMed⌕ Search

Biomedical subjects

E Weeke

Publications and source records attributed to E Weeke.

At least 19 recordsLinked to original sources
PubMed1983

Comparison of a 750 ml spacer and a nebulizer in domiciliary treatment of severe chronic asthma with terbutaline.

Twelve patients with severe chronic obstructive lung disease, participated in this double-blind, cross-over study. Either terbutaline sulphate aerosol or placebo was delivered via a pressurized aerosol with a 750 ml spacer interposed between the actuator and the mouth, or by an electric compressor nebulizer. Each treatment was given for 1 week. The patients recorded PEF and the use of extra terbutaline aerosol while treating themselves at home. All patients completed the treatment periods on terbutaline. Five patients failed to complete the placebo treatment periods because their condition deteriorated. There was no significant difference in bronchodilatation with 5 mg terbutaline using the nebulizer versus 1.5 mg terbutaline using the spacer. We conclude that in the treatment of severe asthma, a pressurized aerosol with a 750 ml spacer can be used either alone, or as a supplement to, treatment with an electric compressor nebulizer.

Adult↗
PubMed1981

Terbutaline depot tablets in asthma. A clinical evaluation.

A sustained release preparation of terbutaline sulphate has been formulated (Bricanyl depot tablets) in order to extend the duration and accordingly change the dosage regimen to twice a day. This presentation gives a summary of a clinical trial performed in order to study effect and side effects of terbutaline depot tablets 7.5 mg twice a day compared to terbutaline tablets 5 mg three times a day. Patients suffering from perennial asthma and with daily requirement of asthma medicine were accepted for the study. The trial was a double-blind cross-over, double dummy and randomized. The tablets were given in two consecutive periods of 7 day's duration each. The effect of terbutaline depot tablets was equal to the effect of the ordinary terbutaline tablets. The indication for using depot tablets in the basic treatment of bronchial asthma is a better patient compliance due to medication twice a day. Furthermore in patients with unstable bronchial asthma and in patients with morning dips in PEF the more stable plasma concentration may perhaps keep the patients in a more steady state.

Adolescent↗
PubMed1979

A comparative study of the bronchodilatating effects of ipratropium and terbutalin inhaled with Monaghan IPPB-M 515 by 19 patients with chronic obstructive airways disease.

The effect of ipratropium (Atrovent) 0.125 mg x 4 daily was compared to terbutalin (Bricanyl) 5 mg x 4 daily, given to 19 patients with chronic obstructive airways disease (15 with chronic bronchitis, 10 bronchial asthma, 7 pulmonary emphysema) as inhalation therapy with Monaghan IPPB-M 515, during 2 treatment periods of 3 days. The investigation was carried out as a controlled, double-blind, cross-over comparison. The effect of treatment was evaluated by measurement of PEFR, symptom scores, including the side-effects and the use of rimiterol MDI for the treatment of acute attacks. The PEFR values were all higher than the initial values (P less than 0.001) during the period of treatment (08.00-20,30 hrs). The highest values were recorded at 16.30 hrs, these were PEFR + 31.7% for the Atrovent period and PEFR + 28.0% for the Bricanyl period. No statistically significant difference was observed in the PEFR, symptom scores, side-effects and the use of rimiterol during the Atrovent and Bricanyl treatment periods. The authors suggest that Atrovent is a wellsuited alternative bronchodilatator, particularly for patients with tremor, muscle cramp, and "inner restlessness" following treatment with a beta 2-stimulator.

Adult↗